Maritech fucoidan to undergo new clinical trial to research immuno-modulating properties

Alissa Marrapodi

Alissa Marrapodi is Industry Insights Contributor, Custom Content Editor, MJH Life Sciences.

Marinova is conducting a new clinical trial, in collaboration with Nutrasource, to further explore the immunomodulatory properties of Maritech fucoidan, a marine polysaccharide found naturally in brown seaweed, in healthy adults.

Marinova (Tasmania, Australia) is conducting a new clinical trial, in collaboration with Nutrasource, to further explore the immunomodulatory properties of Maritech fucoidan, a marine polysaccharide found naturally in brown seaweed, in healthy adults. 

Previous research on Maritech fucoidan has shown that it may:

  • Boost immune responses to vaccines
  • Activate dendritic cells, natural killer cells and T cells
  • Block the entry of coated viruses to cells
  • Reduce lung damage commonly associated with viral infection
  • Support mucosal immune health
  • Dampen allergic responses
  • Modulate stem cell 

The new study is designed to piggyback on existing evidence that suggests Maritech fucoidan acts as an immune priming agent by increasing cytotoxic T cells and natural killer cells, reducing the levels of inflammatory cytokine interleukin-6, and modulating the key market immunoglobulin.

“High-purity, certified organic fucoidan is already included in a multitude of innovative nutritional supplements targeting immune health,” said Marinova’s CEO and managing director, Paul Garrott, in a press release. “Marinova’s investment in this new clinical trial will deepen our understanding of the unique health benefits of Maritech fucoidan.”